Chemistry-aware AI offers new routes in small molecule design
By Drug Target Review
The predictive validity crisis: Pharma’s productivity paradox – Part I
By Dr Jack Scannell (CEO of Etheros Pharmaceuticals Corp), Dr…
Eye movements as objective biomarkers: accelerating CNS drug development
By Dr Eitan Raveh (Vice President of Clinical Partnerships at…
Advancing gene editing: the role of lipid nanoparticles in CRISPR delivery
By the Acuitas Therapeutics team (author details below)
Improving brain resilience: Rab proteins and future treatments
New research has discovered how Rab proteins control the delivery of critical supplies to strengthen neural connections, providing researchers with important insights into memory formation and potential strategies for Alzheimer’s resilience.
Beyond the Lab: Biomarkers Powering Tomorrow’s Therapies
Biomarkers are redefining how precision therapies are discovered, validated and delivered. This exclusive expert-led report reveals how leading teams are using biomarker science to drive faster insights, cleaner data and more targeted treatments – from discovery to diagnostics.
Beyond the Lab: Clinical Trials
Explore how artificial intelligence (AI), biomarkers, and innovative trial technologies are creating a more efficient, data-driven future for drug discovery. From better patient selection to smarter trial design, see how clinical research is evolving to deliver new therapies faster.
The predictive validity crisis: Pharma’s productivity paradox – Part I
By Dr Jack Scannell (CEO of Etheros Pharmaceuticals Corp), Dr…
Eye movements as objective biomarkers: accelerating CNS drug development
By Dr Eitan Raveh (Vice President of Clinical Partnerships at…
Advancing gene editing: the role of lipid nanoparticles in CRISPR…
By the Acuitas Therapeutics team (author details below)